Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022

Latest Articles

  • You have access
    Cardiovascular disease myths and facts
    Jan L. Breslow, MD
    Cleveland Clinic Journal of Medicine June 1998, 65 (6) 286-287;

    Physicians need to overcome the myths that cardiovascular disease is going away and is a good way to die, as these myths are undermining research and prevention efforts.

  • You have access
    Some perspective on Viagramania
    Leslie R. Schover, PHD
    Cleveland Clinic Journal of Medicine June 1998, 65 (6) 331-332;

    The sales of Viagra are not surprising, given that the search for a drug to enhance sexual performance is as old as written history.

  • You have access
    Managing solitary pulmonary nodules
    Prasoon Jain, MD, Salim A. Kathawalla, MD and Alejandro C. Arroliga, MD
    Cleveland Clinic Journal of Medicine June 1998, 65 (6) 315-326;

    The goals of management are to resect malignant tumors while avoiding unnecessary thoracotomy of benign nodules. But sometimes this is not easy.

  • You have access
    Sildenafil (Viagra) for treating male erectile dysfunction
    Mark R. Licht, MD
    Cleveland Clinic Journal of Medicine June 1998, 65 (6) 301-304;

    A brief overview of sildenafil, the first oral drug for treating erectile dysfuntion. With an illustration showing how the drug works.

  • You have access
    The promises and risks of inpatient specialization
    John D. Clough, MD
    Cleveland Clinic Journal of Medicine June 1998, 65 (6) 332-333;

    Much of the benefit of hospitalist care will be lost if we place the emphasis on wringing every last nickel out of the cost of providing care.

  • You have access
    Cancer information and the Internet: Benefits and risks
    Maurie Markman, MD
    Cleveland Clinic Journal of Medicine May 1998, 65 (5) 274-276;

    The Internet has potential to educate the public about health care, Kit also can harm through misleading and deceptive information.

  • You have access
    The connection between chronic fatigue syndrome and neurally mediated hypotension
    William S. Wilke, MD, Fetnat M. Fouad-Tarazi, MD, Joseph M. Cash, MD and Leonard H. Calabrese, DO
    Cleveland Clinic Journal of Medicine May 1998, 65 (5) 261-266;

    Some research indicates that some patients with chronic fatigue syndrome have abnormal vasovagal or vasodepressor responses to upright posture. But subsequent studies have not corroborated these results.

  • You have access
    The EPILOG Trial
    Matthew T. Roe, MD and David J. Moliterno, MD
    Cleveland Clinic Journal of Medicine May 1998, 65 (5) 267-272;

    The platelet glycoprotein Ilb/IIIa inhibitor abciximab, together with heparin in a low, weight-adjusted dose, markedly reduced the risk of acute ischemic complications during angioplasty, without increasing the risk of hemorrhage.

  • You have access
    Dear Colleague
    John D. Clough, MD
    Cleveland Clinic Journal of Medicine May 1998, 65 (5) 226;
  • You have access
    Anorectic drugs and valvular heart disease (January 1998)
    Tsung O. Cheng, MD
    Cleveland Clinic Journal of Medicine May 1998, 65 (5) 277;

Pages

  • Previous
  • Next
  • 1
  • …
  • 439
  • 440
  • 441
  • 442
  • 443
  • 444
  • 445
  • 446
  • 447
  • …
  • 799

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire